METRO MINNESOTA COMMUNITY CLINICAL ONCOLOGY PROGRAM

明尼苏达州社区临床肿瘤学计划（MMCCOP） 代表一个由八家医院组成的财团，通过其国家癌症研究所资助的 社区医院肿瘤计划（“CHOP”）和业务CCOP， 已经开发出一种管理癌症患者的通用方法， 并有一个既定的机制，进入和跟踪病人 治疗和癌症控制方案。财团有一个共同体- 一种能够预测数据的广泛的计算机化数据管理系统 收藏.社区提供5个HMO计划，所有这些都是 在这八家医院中，在一起，八个 医院平均每年接待7500名新的癌症患者。 67名核心研究者，代表肿瘤学，血液学， 放射肿瘤科、泌尿科、妇科肿瘤科、神经科、耳鼻喉科和 结直肠手术，在癌症项目上广泛合作， 开发和协议管理。该机制的工作人员是合格的， 接受过肿瘤学和数据管理方面的培训，并参与了 目前的程序结构和操作的发展。期间 在最近一个国家癌症研究所资助的赠款年度（1993年6月至1994年5月）， 患者（144.7治疗学分/86癌症控制学分）到NCI- 批准的研究。另外64名男性入组前列腺 癌症预防试验和待定信贷（不允许，直到之后 完成3个月的导入期）。MMCCOP打算维持一个 区域性社区和医院联盟， 社区在癌症控制和治疗方面的最新进展。 这将通过将缔约方会议扩大到常设委员会， 外展社区;与医院、基金会、保险公司和 综合服务网络，以发展筹资和偿还 支持参与临床试验; 初级保健医生;提供专业知识，资源和大 制定、实施和评估临床癌症的人口基础 通过与NCI、ECOG、M.D. 安德森，NSABP，URCC和RTOG;改进和扩展当前的MMCCOP 数据管理和通信系统，以提高号码添加水平 研究者参与权责发生制、项目运营和 研究基地活动;确定和招募关键研究人员， 获得少数群体的参与;并增加专业和 非专业社区对CCOP的认识和临床癌症的益处 审判根据过去的经验和改进的癌症控制 实施模式，MMCCOP调查人员打算累计350学分 在第一次NCI批准的癌症治疗和对照研究中， 年，超过了这两类研究的最低要求。

The Metro-Minnesota Community Clinical Oncology Program (MMCCOP) represents a consortium of eight hospitals which, through its NCI-funded Community Hospital Oncology Program ("CHOP") and operational CCOP, has already developed a common approach to the management of cancer patients and has an established mechanism for entering and following patients on treatment and cancer control protocols. The consortium has a community- wide computerized data management system capable of prospective data collection. The community offers 5 HMO programs, all of which are represented among these eight consortium hospitals. Together, the eight hospitals see an average of 7500 new analytic cancer patients per year. The sixty-seven core investigators, representing oncology, hematology, radiation oncology, urology, gynecologic oncology, neurology, ENT, and colorectal surgery, have worked extensively together on cancer program development and protocol management. The MMCCOP staff is qualified and trained in oncology and data management, and has been involved in the development of the current program structure and operation. During the most recent NCI-funded grant year (6/93-5/94), the MMCCOP entered 318 patients (144.7 treatment credits/86 cancer control credits) onto NCI- approved studies. An additional 64 men were enrolled in the Prostate Cancer Prevention Trial and were pending credit (not allowed until after completion of 3 month run-in period). The MMCCOP intends to sustain a region wide community and hospital consortium which provides the community with the most recent advances in cancer control and treatment. This will be accomplished through expansion of the CCOP into established outreach communities; work with hospitals, foundations, insurers and Integrated Service Networks (ISNs) to develop funding and reimbursement support for participation in clinical trials; increased involvement of primary care physicians; providing the expertise, resources, and large population base to develop, implement and evaluate clinical cancer treatment and control trials through affiliation with the NCI, ECOG, M.D. Anderson, NSABP, URCC, and RTOG; improve and expand the current MMCCOP data management and communication system to increase the number add level of participation of the investigators in accrual, program operations and research base activities; identify and recruit key investigators to access minority group participation; and increase the professional and lay community awareness of the CCOP and benefits of clinical cancer trials. Based upon past experience and improved cancer control implementation models, MMCCOP investigators intend to accrue 350 credits onto NCI-approved cancer treatment and control studies during the first year, exceeding the minimum requirements for both types of studies.